New eIF4E inhibitor halts tumor growth by rewiring lipid metabolism
In a development that could reshape how scientists approach one of cancer's most stubborn molecular vulnerabilities, researchers have designed and ...
In a development that could reshape how scientists approach one of cancer's most stubborn molecular vulnerabilities, researchers have designed and ...
Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a ...
In a groundbreaking leap for cancer therapeutics, the VCU Massey Comprehensive Cancer Center has triumphantly concluded the first funding cycle ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine